All lobbying filings

FORBES-TATE

FORBES-TATE filed a Q3 report for GILEAD SCIENCES, INC. on October 18, 2026, reporting $80,000 in lobbying income.

Lobbying for GILEAD SCIENCES, INC. · Specialty biopharmaceutical company.

All filings by FORBES-TATE · Everything GILEAD SCIENCES, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 18, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.